Daily Trend Analysis Reports On: (OTCQB: TTNP), (OTCQB: AAMRQ)
Titan Pharmaceuticals Inc. (OTCQB: TTNP) announced that the majority of Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) members recognized the favorable benefit-risk profile of Probuphine® and voted for approval (10 positive votes, 4 negative votes and 1 abstention).
View full press release